头颈癌放疗或放化疗与神经认知功能缺陷的关联
一项前瞻性纵向研究在加拿大多伦多玛格丽特公主癌症中心纳入80例需根治性放化疗或放疗的头颈癌患者与40例健康对照,于基线及6、12、24个月评估客观神经认知功能与自报症状。结果显示患者多个认知域表现随时间下降,24个月时总体认知功能受损率患者为38%、对照为0%,且缺陷与基线细胞因子无关。
要点
- 头颈癌根治性放疗或放化疗后认知缺陷可持续至2年
- 24个月时总体神经认知功能受损率患者38%、对照0%
- 应向患者告知该潜在风险并开展后续干预研究
核心结论
- 头颈癌幸存者在根治性放化疗或放疗后2年内仍存在神经认知后遗症,患者与医疗团队应知晓这一潜在风险,需进一步研究避免、减少和补偿认知下降的策略。
研究设计与样本
- 前瞻性纵向研究,纳入80例组织学证实、需根治性放化疗或放疗的头颈癌患者及40例健康对照,在基线及6、12、24个月共4次评估神经认知功能与自报症状,地点为加拿大多伦多玛格丽特公主癌症中心。
主要发现
- 患者与对照在部分认知域的平均表现存在显著差异且患者缺陷随时间增加,涉及智力容量、注意力/短时注意广度、言语记忆、执行功能和总体认知功能复合评分。
- 24个月时患者总体神经认知功能受损率为38%,对照为0%。
- 神经认知缺陷与基线细胞因子无关。
关键数值与推荐
- 智力容量效应量(95%CI):6个月-0.46(-0.64至0.30)、12个月-0.51(-0.72至-0.30)、24个月-0.70(-0.92至-0.49)。
- 注意力/短时注意广度:6个月-0.19(-0.37至0.00)、12个月-0.38(-0.55至-0.21)、24个月-0.54(-0.71至-0.37)。
- 言语记忆:6个月-0.16(-0.33至0.02)、12个月-0.38(-0.64至-0.12)、24个月-0.53(-0.74至-0.32)。
- 执行功能:6个月-0.14(-0.27至0.00)、12个月-0.34(-0.52至-0.16)、24个月-0.43(-0.64至-0.22)。
- 总体认知功能复合:6个月-0.38(-0.55至-0.22)、12个月-0.75(-0.92至-0.58)、24个月-1.06(-1.26至-0.86)。
临床怎么用
- 对接受根治性放疗或放化疗的头颈癌患者,应在治疗前告知神经认知功能下降的潜在风险。
- 治疗后可关注智力容量、注意力、言语记忆、执行功能等认知域变化,必要时进行认知评估与随访。
局限性
- 原文未能从摘要中提取明确的局限性描述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Neurocognitive deficits (NCD) have been observed in noncentral nervous system cancers, yet short- and long-term neurocognitive data on patients treated for head and neck cancer (HNC) are lacking. OBJECTIVE: To assess objective neurocognitive function before and after definitive radiation therapy for HNC. DESIGN, SETTING, AND PARTICIPANTS: In a prospective, longitudinal study, neurocognitive function and self-reported symptoms were assessed in 80 patients with histologically proven HNC requiring definitive chemoradiotherapy or radiotherapy and in 40 healthy controls 4 times (baseline, 6, 12, and 24 months after baseline) prior to commencing treatment at Princess Margaret Cancer Centre, Toronto, Canada. MAIN OUTCOMES AND MEASURES: Neurocognitive test scores were converted to age-corrected z scores (mean, 0; standard deviation, 1) and reported as mean scores, standardized regression-based scores, and frequencies of impairments in intellectual capacity, concentration, memory, executive function, processing speed, and motor dexterity. Multivariable analysis was used to identify factors associated with NCD 2 years after treatment. RESULTS: Eighty patients and 40 healthy controls enrolled. Analyses revealed significant differences between patient and control mean performance in some domains, with patient deficits increasing over time: intellectual capacity (Cohen d, effect sizes [95% CIs] of -0.46 [-0.64 to 0.30], -0.51 [-0.72 to -0.30], and -0.70 [-0.92 to -0.49] for time points 6, 12, and 24 months, respectively); concentration/short-term attention span (-0.19 [-0.37 to 0.00], -0.38 [-0.55 to -0.21], -0.54 [-0.71 to -0.37]); verbal memory (-0.16 [-0.33 to 0.02], -0.38 [-0.64 to -0.12], -0.53 [-0.74 to -0.32]); executive function (-0.14 [-0.27 to 0.00], -0.34 [-0.52 to -0.16], -0.43 [-0.64 to -0.22]), and global cognitive function composite (-0.38 [-0.55 to -0.22], -0.75 [-0.92 to -0.58], -1.06 [-1.26 to -0.86]). There was an increased rate of impaired global neurocognitive functioning among patients (38%) at 24 months compared with controls (0%). Neurocognitive deficits were not associated with baseline cytokines. CONCLUSIONS AND RELEVANCE: Head and neck cancer survivors have neurocognitive sequelae up to 2 years after definitive chemoradiotherapy or radiation treatment. Patients and health care teams should know about such potential risks. Further research is warranted in search of strategies to avoid, reduce, and compensate for declines.
引用
- Zer A, Pond GR, Razak ARA, et al. Association of Neurocognitive Deficits With Radiotherapy or Chemoradiotherapy for Patients With Head and Neck Cancer. JAMA Otolaryngol Head Neck Surg. 2018. PMID: 29167901. doi:10.1001/jamaoto.2017.2235
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。